School of Medicine


Showing 1-10 of 37 Results

  • Myriam Amsallem

    Myriam Amsallem

    Postdoctoral Research Fellow, Cardiovascular Medicine

    Bio Myriam Amsallem MD PhD is a cardiologist specialized in cardiac imaging. She has an interest in heart failure, cardioimmunology and early detection of pulmonary hypertension using imaging and circulating biomarkers. She is currently working on studies on cardiac remodeling pulmonary hypertension with the goal of understanding the influence of inflammation and finding early biomarkers of remodeling. She also has a special interest in educational projects to improve the quality of imaging methodology.

  • Mohsen Fathzadeh

    Mohsen Fathzadeh

    Postdoctoral Research Fellow, Cardiovascular Medicine

    Current Research and Scholarly Interests Here at Stanford cardiovascular medicine, I have been pursuing the career of characterizing cardiometabolic disease genes by joining my current advisors who co-lead international consortium on Genome-Wide Association Studies (GWAS) of insulin resistance (GENESIS) as the underlying risk factor of type 2 diabetes and metabolic syndrome. Currently, we are scrutinizing the post-genomic studies of diabetes and glycemic traits associated loci by means of deep phenotyping approach i.e. multi-OMICs. I am, in particular, eager to harness these technologies to unravel the underlying cause of diabetes and the development of insulin resistance in the presence or absence (lipodystrophy) of obesity.
    Here are two examples of our current theme of research we are following:
    - Demonstrate FAM13A as the causative gene linking fasting insulin level and body fat distribution.
    - Defined pathophysiological link of Human NAT2 and mouse orthologue, Nat1, to mitochondria function and cardiometabolic risk.

  • Gentaro Ikeda

    Gentaro Ikeda

    Postdoctoral Research Fellow, Cardiovascular Medicine

    Bio My long-term goal is to become a physician scientist and develop innovative diagnostic and therapeutic modalities for patients with cardiovascular disease. Based on my experience as a cardiologist for the past 5 years, I have become aware of major clinical shortcomings, specifically in the current pharmaceutical therapies for myocardial infarction (MI) and chronic heart failure (HF). Some evidence-based drug therapies, including ?-blockers, ivabradine, and renin?angiotensin?aldosterone antagonists are difficult to apply to critical patients due to adverse side effects. Drugs that have shown efficacy in basic animal experiments have failed to show significant benefits in clinical trials. To address these problems, I moved to academia to conduct translational research. During my graduate training in the Egashira Lab, I focused on drug delivery systems (DDS) that target mitochondria in animal models of MI. I obtained advanced skills in molecular biology, mitochondrial bioenergetics, and animal surgery. I realized the importance of translational research and the great potential of DDS to overcome many clinical problems. I developed nanoparticle-mediated DDS containing cyclosporine for the treatment of patients with MI. I published a first author paper and received academic awards for my novel science. Since becoming a postdoctoral fellow in the Yang Lab, I have continued to build upon my previous training in translational research. I am currently developing an innovative therapy, namely, extracellular vesicles-mediated mitochondrial transfer for the failing heart.

Footer Links:

Stanford Medicine Resources: